Clinical Trials Browser

Phase 2 × OTHER_GOV × Burkitt Lymphoma × Clear all

NCT05648019 2023-03-09

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma